Stemtech (OTCQB: STEK), an innovative stemceutical(TM) company and a pioneer in the field of stem cell nutrition, has introduced its new CellectOne(TM) innovative and cutting-edge skincare line; Stemtech also launched the first offering in the product line: the Rapid Renew Stem Cell Peptide Night Cream. Stemtech is partnering with Life Factor Research to create product lines designed to build a dedicated and naturally expanding following. This new product line and initial product offering is the foundation of that strategic plan. “Introducing a new product is always a significant mark of advancement,” said Stemtech Corporation president and COO John W. Meyer in the press release. “This new branding of the Stemtech Corporation stem cell skincare line under brand CellectOne is a great step forward. The strategic vision of Stemtech continues to become reality with the Life Factor Research contributions of new cutting-edge science and technology. We are proud to introduce the first of many new products to come. CellectOne products are developed by Stemtech’s new Research and Development Division, Life Factor Research. The science and technology used to create the Rapid Renew Stem Cell Peptide Night Cream is a tremendous, all-natural, ingredient-based product which penetrates deeply into the skin layers for improving skin health.”
To view the full press release, visit https://ibn.fm/2BGNg
About Stemtech Corp.
Stemtech Corporation, a leading stemceutical company with a direct-sales distribution model, was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International Inc., which was established in 2005. From 2010 through 2015, Stemtech International Inc. was recognized four times on the Inc. 5000 Fastest-Growing Companies list. In 2018, Stemtech underwent an extensive executive reorganization and continued operations under new leadership as Stemtech Corporation. In August 2021, Stemtech became a publicly traded company and has expanded business opportunities for its independent business partners, who may earn incomes by sharing Stemtech products. The company markets its products under the following brands: RCM System, stemrelease3(TM), Stemflo(R) MigraStem, OraStem(R) (Oral Health Care), CellectOne (skincare products) and D-Fuze(TM) (EMF blocker). Its stemceutical products are all natural, plant based and manufactured under Current Good Manufacturing Practices under the auspices of the Dietary Supplement Health and Education Act. For more information about the company, please visit www.Stemtech.com.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork